Abstract:ObjectivePreeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists.Study DesignCandidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve.ResultsWe observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age.ConclusionWe have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program. ObjectivePreeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists. Preeclampsia is a condition arising from poor placentation and manifests itself as hypertension and proteinuria later in pregnancy. There are currently no specific laboratory based tests to diagnose preeclampsia for timely management or use of interventions. As a result, preeclampsia is a leading cause of preterm birth as well as maternal and fetal death. Our objective is to develop a serological protein assay to allow early recognition and referral of preeclamptic patients to Maternal Fetal Medicine specialists. Study DesignCandidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve. Candidate biomarkers were revealed by ensemble analysis of gene expression and proteomics profiling of preeclampsia samples. Biomarkers were further qualified with enzyme-linked immunosorbent assays (ELISA) using serum samples from 33 preeclampsia subjects and 31 pregnant controls matched by parity, ethnicity, and gestational age (range 24-40 weeks). A five-protein serological panel, comprised of both novel and investigational proteins, was constructed by the application of a genetic algorithm optimized for its ability to accurately diagnose preeclampsia as defined by the area under the receiving operating characteristic curve. ResultsWe observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age. We observed better clustering and separation between samples from preeclamptic and non-preeclamptic patients compared to previously described, investigational diagnostic tests. Separation between patients groups was more pronounced earlier in gestational age. ConclusionWe have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program. We have identified a serological protein panel capable of diagnosing both early and late onset preeclampsia. Further characterization of the novel panel analytes yielded mechanistic insights in preeclampsia, therefore, explaining the observed sensitivity and specificity across gestational ages. Future prospective validation can drive the translation of our serological panel into practical bedside clinical utilities for preeclampsia care. The work was supported by grants from the March of Dimes and Stanford University Spark Program.

Parallel Assessment Of Circulatory Fetal Dna And Corticotropin-Releasing Hormone Mrna In Early- And Late-Onset Preeclampsia

Maternal circulatory levels of procalcitonin, uric acid, and lipid profile in Early-onset preeclampsia and Late-onset preeclampsia

The Feto-Maternal Outcomes and Incidence of Early-and Late-Onset Preeclampsia

Pregnancy Outcome in Early versus Late Onset Preeclampsia

Body mass index, lipid profile, and endothelial dysfunction gene polymorphism in women with early-onset and late-onset preeclampsia

Study on the Relation Between Concentration of Circulating Non-Host Fetal DNA in Pregnant Women and Pre-Eclampsia

Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia

642: Transcriptomics and Proteomics Ensemble Analyses Reveal Serological Protein Panel for Preeclampsia Diagnosis

The clinical features and prognostic analysis of early-onset preeclampsia

Clinical presentation, maternal-fetal, and neonatal outcomes of early-onset versus late onset preeclampsia-eclampsia syndrome in a teaching hospital in a low-resource setting: A retrospective cohort study

Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies

Alterations in Serum Adipocyte Fatty Acid Binding Protein and Retinol Binding Protein-4 in Normal Pregnancy and Preeclampsia.

High-throughput methylome analysis reveals differential methylation for early and late onset preeclampsia for mothers and their children

Quantification of Maternal Serum Cell-Free Fetal DNA in Early-Onset Preeclampsia.

Analyzing clinical features and forecasting pregnancy outcomes of early-onset severe preeclampsia

Circulatory Nucleosome Levels Are Significantly Increased in Early and Late-Onset Preeclampsia.

THE LEVELS OF CIRCULATORY FETAL DNA IN MATERNAL PLASMA ARE ELEVATED PRIOR TO THE ONSET OF PREECLAMPSIA

Alterations in fibrin formation and fibrinolysis in early onset-preeclampsia: Association with disease severity

Large Scale Analysis of Circulatory Fetal Dna Concentrations in Pregnancies Which Subsequently Develop Preeclampsia Using Two Y Chromosome Specific Real-Time Pcr Assays

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia